Immobilization of L-asparaginase into a biocompatible poly(ethylene glycol)-albumin hydrogel: evaluation of performance in vivo.
The L-asparaginase of Escherichia coli (ASNase) is currently used in combination with antineoplastic drugs to treat various lymphoblastic leukaemias. However, its use is limited by severe immunological reactions and the short serum half-life associated with the enzyme. Immobilization of ASNase into a biocompatible matrix can greatly decrease the immunogenicity of the enzyme, increase its half-life in vivo and its therapeutic index. Thus the E. coli ASNase was immobilized in a biocompatible hydrogel made of rat serum albumin and poly(ethylene glycol) (PEG; molecular mass 10 kDa). The effectiveness of this enzymic bioreactor to deplete serum L-asparagine was evaluated after its peritoneal implantation in rats. Seven units of immobilized ASNase/rat depleted serum asparagine to an undetectable level (< 1 microM) during 6 days, while 5 units of immobilized ASNase/rat decreased the level of serum asparagine by 85-90% during at least 2 days. Under both conditions asparagine levels returned to normal about 10 days after surgery, and hydrogels still retained 80% of their enzymic activity when assayed in vitro. After 10-14 days in vivo, hydrogels became opaque and surrounded by a fibrotic capsule with a few inflammatory sites. Nevertheless, the enzymic hydrogel showed great stability in vivo, and, after 4 months of implantation, 12% of the initial ASNase activity was still present. At 6 months, histological analysis showed stabilization of the fibrotic capsule thickness. Assays on the levels of ASNase and asparagine synthetase indicated an induction of the latter activity, mainly in the pancreas when compared with the level observed in spleen or liver. ELISA tests at 28 days and 120 days showed the presence of anti-ASNase (and, in lower amounts, anti-PEG) antibodies in sera of implanted rats. As observed with other enzyme-immobilization systems used in vivo, the formation of fibroblast-like cell layers around the implant, which block the translocation of the substrate into the enzymic matrix, is the major factor affecting the performance and longevity of the bioreactor.
Jean-François
J
J
Département de Chimie-Biochimie, Université du Québec, Montréal, Canada.
D'Urso
E M
EM
Fortier
G
G
D000418:Albumins; D000818:Animals; D000917:Antibody Formation; D000970:Antineoplastic Agents / Q000008:administration & dosage; D001215:Asparaginase / Q000008:administration & dosage* / Q000276:immunology / Q000378:metabolism; D001216:Asparagine / Q000097:blood; D001217:Aspartate-Ammonia Ligase / Q000378:metabolism; D001672:Biocompatible Materials; D019149:Bioreactors; D004343:Drug Implants; D004795:Enzyme Stability; D004800:Enzymes, Immobilized; D004926:Escherichia coli / Q000201:enzymology; D005069:Evaluation Studies as Topic; D005782:Gels; D006801:Humans; D010529:Peritoneal Cavity; D011092:Polyethylene Glycols; D051381:Rats; D017207:Rats, Sprague-Dawley; D014018:Tissue Distribution
D000418:Albumins; D000970:Antineoplastic Agents; D001672:Biocompatible Materials; D004343:Drug Implants; D004800:Enzymes, Immobilized; D005782:Gels; D011092:Polyethylene Glycols; D001216:Asparagine; D001215:Asparaginase; D001217:Aspartate-Ammonia Ligase